Assembly Biosciences (ASMB) AI Stock Analysis

• Market Cap: $557.71M
• Dividend Yield: N/A
• Average Volume (3M): 164.41K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.39
• Revenue Growth: 31.30%
• EPS Growth: 32.79%
• Country: US
• Employees: 73
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.72
• Shares Outstanding: 15,817,140
• 10 Day Avg. Volume: 178,321
• 30 Day Avg. Volume: 164,409
• PEG Ratio: 0.05
• Price to Book (P/B): 2.84
• Price to Sales (P/S): 3.32
• P/FCF Ratio: -1.85
• Enterprise Value/Market Cap: 0.12
• Enterprise Value/Revenue: 1.79
• Enterprise Value/Gross Profit: 9.82
• Enterprise Value/Ebitda: -1.60
• 1Y Price Target: $41.75
• Price Target Upside: 18.41% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: $36.00 ▲(2.10% Upside)

Assembly Biosciences' overall stock score is primarily impacted by its financial instability, with significant challenges in revenue generation and profitability. However, the positive technical indicators and promising clinical trial results provide some optimism. The valuation remains weak due to ongoing losses, but the potential market impact of new drug developments offers a positive outlook.

Positive Factors

Positive Clinical Trial Results

Successful Phase 1b results for HSV treatments indicate potential for strong future market positioning in antiviral therapeutics, enhancing long-term growth prospects.

Strategic Partnerships

Strategic alliances offer financial support and expertise, facilitating drug development and commercialization, which can drive sustainable revenue growth.

Focus on Unmet Medical Needs

Targeting unmet needs in HBV therapies can lead to significant market opportunities, supporting long-term revenue potential as products advance through clinical stages.

Negative Factors

Financial Instability

Persistent financial distress with no revenue and negative cash flows threatens liquidity and operational sustainability, necessitating strategic reassessment.

Declining Equity

Significant decline in equity reflects potential risk and financial instability, limiting the company's ability to invest in growth and innovation.

Negative Cash Flow

Negative cash flow indicates liquidity challenges, hindering the company's capacity to fund operations and invest in future growth opportunities.

Assembly Biosciences Business Overview & Revenue Model

Company Description

Assembly Biosciences, Inc. (ASMB) is a biotechnology company focused on developing innovative therapies for viral diseases, primarily targeting hepatitis B virus (HBV) infections. The company operates in the biopharmaceutical sector and is dedicated to advancing its proprietary drug candidates aimed at eradicating HBV and addressing other chronic viral infections. Assembly Biosciences leverages its expertise in virology and immunology to create therapies that can potentially cure these conditions.

How the Company Makes Money

Assembly Biosciences generates revenue through a combination of research and development funding, collaborations and partnerships with other pharmaceutical companies, and potential future product sales. The company often enters into strategic alliances with larger biopharmaceutical firms to co-develop its drug candidates, which can provide upfront payments, milestone payments as development progresses, and royalties on future sales if the products are commercialized. Additionally, Assembly Biosciences may receive grants or funding from governmental or non-profit organizations to support its research initiatives. Their focus on HBV therapies positions them within a market that has significant unmet needs, which can enhance their potential for revenue generation once their products move through clinical trials and towards commercialization.

Assembly Biosciences Financial Statement Overview

Summary

Assembly Biosciences exhibits financial distress across key areas. The absence of revenue in recent years, combined with enduring net losses and negative cash flows, suggests significant profitability and liquidity challenges. While leverage remains low, declining equity and assets reflect potential financial instability, requiring strategic reassessment.

Income Statement

Assembly Biosciences has faced significant challenges with consistent revenue declines from $79.1M in 2020 to $0 in 2022 and 2024, indicating potential instability. The company has struggled with persistent net losses and negative profit margins, including a net profit margin of -100% in 2024. These factors highlight major profitability issues.

Balance Sheet

While the company maintains a reasonable equity ratio of 28% in 2024, indicative of some financial stability, the declining stockholders' equity from $240.6M in 2020 to $33.4M in 2024 raises concerns. A relatively low debt-to-equity ratio of 0.09 in 2024 suggests manageable leverage, but the shrinking equity indicates potential risk.

Cash Flow

Assembly Biosciences experiences significant volatility in free cash flow, with figures dropping sharply from $22.5M in 2023 to -$51.1M in 2024. The negative operating cash flow and free cash flow pose risks to future liquidity and financial health.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	37.19M	28.52M	7.16M	0.00	6.25M	79.11M
Gross Profit	6.79M	28.52M	-41.74M	-69.08M	6.25M	-22.23M
EBITDA	-41.63M	-45.29M	-64.20M	-92.52M	-90.58M	-58.40M
Net Income	-38.55M	-40.18M	-61.23M	-93.09M	-129.85M	-62.15M
Balance Sheet
Total Assets	240.00M	119.17M	136.82M	101.79M	191.06M	283.25M
Cash, Cash Equivalents and Short-Term Investments	232.56M	112.08M	130.25M	91.61M	146.63M	216.41M
Total Debt	2.75M	3.09M	2.34M	3.46M	6.48M	10.13M
Total Liabilities	57.30M	85.81M	95.73M	19.13M	22.13M	42.68M
Stockholders Equity	182.69M	33.36M	41.10M	82.66M	168.93M	240.58M
Cash Flow
Free Cash Flow	-55.78M	-51.15M	22.49M	-84.56M	-96.49M	-65.18M
Operating Cash Flow	-55.74M	-51.12M	22.74M	-84.46M	-93.40M	-62.96M
Investing Cash Flow	-141.39M	40.17M	-69.14M	90.64M	26.52M	68.07M
Financing Cash Flow	191.21M	29.45M	13.82M	614.00K	53.06M	7.60M

Assembly Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 35.26
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ASMB, the sentiment is Positive. The current price of 35.26 is below the 20-day moving average (MA) of 35.46, above the 50-day MA of 33.06, and above the 200-day MA of 21.16, indicating a neutral trend. The MACD of 0.12 indicates Positive momentum. The RSI at 53.77 is Neutral, neither overbought nor oversold. The STOCH value of 17.41 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ASMB.

Assembly Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ASMB	53 Neutral	$557.71M	-7.34	-36.94%	―	31.30%	32.79%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
QSI	50 Neutral	$273.67M	-1.93	-52.44%	―	40.20%	-4.07%
BNTC	47 Neutral	$389.42M	-11.44	-43.71%	―	―	80.95%
LXEO	38 Underperform	$755.42M	-3.83	-80.69%	―	―	4.97%
ANNX	38 Underperform	$748.25M	-3.67	-83.98%	―	―	-35.62%
VOR	33 Underperform	$271.91M	-0.03	―	―	―	-1072.48%

Assembly Biosciences Corporate Events

Assembly Biosciences Reports Positive Phase 1b Results

On December 8, 2025, Assembly Biosciences announced positive interim results from Phase 1b clinical studies of its investigational herpes simplex virus (HSV) helicase-primase inhibitors, ABI-1179 and ABI-5366, for recurrent genital herpes. The studies demonstrated significant reductions in HSV-2 shedding rates and virologically confirmed genital lesion rates compared to placebo, with ABI-1179 showing a 98% reduction in shedding rate and ABI-5366 showing a 76% reduction. Both candidates were well-tolerated, and the company is progressing Phase 2 enabling activities for ABI-1179 and planning longer-duration Phase 2 studies for ABI-5366, potentially impacting their market positioning in the antiviral therapeutics sector.